Emanuele Ostuni, Novartis Oncology
Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the…
InFocus Articles
Cell & Gene
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a…
Big Pharma’s Quest for Blockbuster CAR-T
It has been a full three years since, first Novartis, then Gilead, took the medical world by storm by gaining FDA…
Taking Cell & Gene Mainstream
With the genomics revolution now entering full swing, expectations for the future of cell and gene therapy have…
Making CAR-T Therapy Affordable
While CAR-T therapies may well constitute the frontrunners in an amazing fresh wave of cell-based biomedical…
The Scalability and Manufacturing Barrier
Long playing second fiddle to R&D and considered to be the more mundane segment of the pharma value chain,…
The Power of Cell & Gene
Cell and gene therapies are fast emerging as one of the most prospective and keenly anticipated areas of biologic…
Cell & Gene Therapy Manufacturing: Critical Challenges, Innovative…
Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and…
Artificial Intelligence in Healthcare M&A: On the Rise
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and…
Life Sciences’ Growing Demand for AI Assets
Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company…
Christina M. Busmalis of IBM Watson Health
IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific…
Challenges to AI in Life Sciences
With so many wild predictions being bandied around about AI’s potential to radically transform healthcare for the…